Automated Pharmacy Record Linkage in The Netherlands

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 311-322

  Leufkens, Hubert G ^a   Urquhart, John ^b,c,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c AARDEX Group   (Switzerland)

^d NONE   (United States)

Author keywords

Automated pharmacy record linkage in The Netherlands; Drug exposure ascertainment; European Medicines Agency (EMEA); Individual patient characteristic identification; National electronic patient dossier (EPD); PHARMO and medical record linkage; Population based case control studies; PREVEND (Prevention of Renal and Vascular End stage Disease) study; The Netherlands drug regulatory system

Indexed keywords

EID: 84889416330     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch20     Document Type: Chapter

References (63)

1. Kok FJ, Vandenbroucke JP, Van der Heide-Wessel C, Van der Heide RM. Dietary sodium, calcium, and potassium and blood pressure. Am J Epidemiol 1986; 123: 134-8.
2. Jansen PAF, Schulte BPM, Meyboom RHB, Gribnau FWJ. Antihypertensive treatment as a possible cause of stroke in the elderly. Age Ageing 1986; 15: 129-38.
3. Ouweland FA van, Gribnau FWJ. Nonsteroidal anti-inflammatory drugs as a prognostic factor in acute pulmonary edema. Arch Intern Med 1987; 147: 176-9.
4. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158: 1108-12.
5. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002; 162: 265-70.
6. Vandenbroucke JP, Valkenburg HA, Boersma JW, Cats A, Festen JJM, Huber-Bruning O et al. Oral contraceptives and rheumatoid arthritis: further evidence for a preventive effect. Lancet 1982; ii: 839-42.
7. Hazes JMW, Dijkmans BAC, Vandenbroucke JP, Vries RPR, Cats A. Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis Rheum 1990; 33: 173-9.
8. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
9. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-8.
10. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787-93.
11. van der Klauw MM, Stricker BH, Herings RM, Cost WS, Valkenburg HA, Wilson JH. A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol 1993; 35: 400-8.
12. Egberts TC, Smulders M, de Koning FH, Meyboom RH, Leufkens HG. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996; 313: 530-1.
13. De Bruin ML, van Puijenbroek EP, Egberts AC, Hoes AW, Leufkens HG. Non-sedating antihistamine drugs and cardiac arrhythmias-biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol 2002; 53: 370-4.
14. van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf 2003; 26: 293-301.
15. Haayer-Ruskamp FM. Drug utilization studies in The Netherlands. Pharm Weekbl Sci 1990; 12: 91-6.
16. Hekster YA, Vree TB. Drug utilization research in clinical practice. Drug Intell Clin Pharm 1986; 20: 679-82.
17. Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994; 46: 433-7.
18. Ellwood P. Shattuck lecture: outcomes management. N Engl J Med 1988; 318: 1549-56.
19. Schrijvers AJP, ed., Health and Health Care in The Netherlands. A Critical Self-Assessment by Dutch Experts in the Medical and Health Sciences. Utrecht: De Tijdstroom, 1998.
20. Zwartvan Rijkom JE, Leufkens HG, Busschbach JJ, Broekmans AW, Rutten FF. Differences in attitudes, knowledge and use of economic evaluations in decision making in The Netherlands. The Dutch results from the EUROMET Project Pharmacoeconomics 2000; 18: 149-60.
21. Leufkens HG, Haaijer-Ruskamp F, Bakker A, Dukes G. Scenario analysis of the future of medicines. BMJ 1994; 309: 1137-40.
22. Hoes AW, Grobbee DE, Lubsen J, Man in't Veld AJ, van der Does E, Hofman A. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123: 481-7.
23. Van der Lei J, Duisterhout JS, Westerhof HP et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993; 119: 1036-41.
24. Jong GW 't, Stricker BH, Sturkenboom MC. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ 2004; 328: 931.
25. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004; 164: 1293-7.
26. Borden EK, Lee JG. A methodologic study of postmarketing drug evaluation using a pharmacy-based approach. J Chron Dis 1982; 35: 803.
27. Stricker BHCh, Barendregt M, Herings RMC, De Jong-van den Berg LTW, Cornel MC, De Smet PAGM. Ad hoc tracing of a cohort of patients exposed to acitretine (Neotigason) on a nation wide scale. Eur J Clin Pharmacol 1992; 42: 555-7.
28. Souverein PC, Egberts AC, Sturkenboom MC, Meuleman EJ, Leufkens HG, Urquhart J. The Dutch cohort of sildenafil users: baseline characteristics. Br J Urology 2001; 87: 648-53.
29. Urquhart J. Time to take our medicines, seriously (inaugural professorial lecture, University of Limburg, April 3, 1992). Pharm Weekbl 1992; 127: 769-76.
30. Leufkens HG, Ruter EM, Ameling CB, Hekster YA, Bakker A. Linkage of pharmacy data on heavy users of nonsteroidal anti-inflammatory drugs to information from general practitioners. J Pharmacoepidemiol 1991; 2: 67-77.
31. Petri H, Leufkens H, Naus J, Silkens R, Hessen P van, Urquhart J. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990; 43: 433-9.
32. Herings RMC, Stricker BHC, Nap G, Bakker A. Pharmacomorbidity linkage: a feasibility study comparing morbidity in two pharmacy-based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-40.
33. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195-8.
34. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-22.
35. van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003; 326: 255-6.
36. Beiderbeck-Noll AB, Sturkenboom MC, van der Linden PD, Herings RM, Hofman A, Coebergh JW et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer 2003; 39: 98-105.
37. Schoofs MW, van der Klift M, Hofman A, de Laet CE, Herings RM, Stijnen T et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139: 476-82.
38. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT. PREVEND Study Group. The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol 2002; 53: 31-6.
39. Atthobari J, Monster TB, de Jong PE, de Jong-van den Berg LT. PREVEND Study Group. The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs. Br J Clin Pharmacol 2004; 57: 328-36.
40. Maitland-van der Zee AH, de Boer A, Leufkens HG. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol 2000; 410: 121-30.
41. Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen Mj M, de Boer A. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 2004; 75: 394-402.
42. Visser LE, Schaik RH, Vliet Mv M, Trienekens PH, De Smet PA, Vulto AG et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61-6.
43. Movig KL, Leufkens HG, Lenderink AW, Egberts AC. Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia. J Clin Epidemiol 2003; 56: 530-5.
44. De Jong van den Berg LTW, van den Berg PB, Haayer-Ruskamp FM, Dukes MNG, Wesseling H. Investigating drug use in pregnancy. Methodological problems and perspectives. Pharm Weekbl Sci 1991; 13: 32-8.
45. Lau HS, Boer de A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619-25.
46. Linden PD van der, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163: 1801-7.
47. Staa TP van, Abenhaim L, Leufkens HG. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol 1994; 47: 183-9.
48. Meijer WE, Bouvy ML, Heerdink ER, Urquhart J, Leufkens HG. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 179: 519-22.
49. Klerk E de, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003; 30: 44-54.
50. Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Delivery Rev 1998; 33: 207-19.
51. Inman B. Comparative study of five NSAIDs. PEM News 1985; 3: 3-134.
52. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577-81.
53. Leufkens HG, Urquhart J, Stricker BHCh, Bakker A, Petri H. Channeling of controlled release formulation of ketoprofen (OSCOREL) in patients with history of gastrointestinal problems. J Epidemiol Community Health 1992; 46: 428-32.
54. Petri H, Urquhart J, Herings R, Bakker A. Characteristics of patients prescribed three different inhalational beta-2 agonists: an example of the channeling phenomenon. Postmarket Surveill 1991; 5: 57-65.
55. Egberts ACG, Lenderink AW, Koning de FHP, Leufkens HGM. Channeling of three newly introduced antidepressants to patients not responding satisfactorily of previous treatment. J Clin Psychopharmacol 1997; 17: 149-55.
56. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997; 315: 1151-4.
57. Feenstra J, Grobbee DE, in 't Veld BA, Stricker BHCh. Confounding by contraindication in a nationwide cohort study of risk for death in patients taking ibopamine. Ann Intern Med 2001; 134: 569-72.
58. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003; 12: 423-4.
59. Schelleman H, Klungel OH, Kromhout D, de Boer A, Stricker BH, Verschuren WM. Prevalence and determinants of undertreatment of hypertension in the Netherlands. J Hum Hypertens 2004; 18: 317-24.
60. Klungel OH, Stricker BH, Paes AH, Seidell JC, Bakker A, Vok Z et al. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke 1999; 30: 1312-18.
61. Mantel-Teeuwisse AK, Klungel OH, Egberts TC, Verschuren WM, Porsius AJ, de Boer A. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Saf 2004; 27: 63-70.
62. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61: 275-91.
63. Stricker BHCh, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 329: 44-7.